If you take a GLP-1 through your employer’s health plan, the only thing that decides your 2027 cost is what your own plan documents say. Not the headlines. Three documents answer it: the Summary of Benefits and Coverage, your plan’s prescription drug list, and your open enrollment packet. This guide shows where each one comes from, which line to read, and what to ask your benefits team before enrollment closes. It covers cost, coverage, and paperwork only — nothing about which medication to take or whether to stay on one. That is between you and your prescriber.
What is actually happening to employer GLP-1 coverage in 2027?
Employers are trimming, not stampeding for the exit.
In a Business Group on Health survey of 105 large employers, fielded February to March 2026, 67% covered GLP-1s for weight management. Of those, 72% said they were likely to continue that coverage in 2027 and 10% said they likely would not (Business Group on Health, 2026 Employer Health Care Strategy Survey, fielded February to March 2026).1
Mercer found a similar picture among employers with 500 or more employees. In its survey of 604 U.S. employers, fielded April 15 to May 8, 2026, 6% of these large employers dropped weight-loss GLP-1 coverage for 2026, and another 5% planned to drop it for 2027 or were considering it. Another 27% had tightened utilization controls or planned to in 2027. Mercer says 49% of large employers covered these drugs for weight loss in 2025 (Mercer, June 11, 2026).2
KFF’s 2026 Employer Health Benefits Survey, published October 22, 2026, gives the broadest view. Among firms with 200 or more workers, 18% cover GLP-1s for weight loss, about the same as 19% in 2025. Among the firms that do not cover them, 12% said they had stopped covering them in the past 12 months, and 79% said they were not likely to start within a year (KFF, October 22, 2026).11 The numbers differ from the other two surveys because each one samples a different group of employers.
Cost is the pressure behind these decisions. Mercer’s preliminary 2026 survey results, released September 2, 2026, project that total health benefit cost per employee will rise 8.2% in 2027. Mercer estimates that rising GLP-1 use accounts for a full percentage point of that growth, and says some employers chose to drop this coverage for next year (Mercer, September 2, 2026).12
So the likeliest change at your employer is not a cut. It is a tighter rule.
Which documents tell you whether your plan is changing?
1. The Summary of Benefits and Coverage (SBC). Every group health plan has to give you one under Section 2715 of the Public Health Service Act (CMS, April 2026). It comes from your plan or insurer, usually through your employer’s benefits site. When coverage renews automatically, CMS says a new SBC generally must be provided at least 30 days before the new plan year begins. You can also ask for one any time, and CMS says plans must generally deliver it within seven business days of the request.3 If you want to see the standard format before yours arrives, the Department of Labor posts the SBC template and the uniform glossary of coverage terms.4
Read two parts. In the “Common Medical Events” chart, find the row “If you need drugs to treat your illness or condition” — that is where your prescription tiers and copays live. Then read “Excluded Services & Other Covered Services,” which lists what the plan does not cover (CMS, April 2026). The SBC is a summary, so it may not name your specific drug. That is what the next document is for.
2. The prescription drug list (formulary). This comes from the pharmacy benefit manager, not usually from HR, and it is the only document that names medications. Search the 2027 list for your drug by brand name. You are looking for three things next to it: whether it appears at all, its tier, and any codes in the notes column — usually PA for prior authorization, ST for step therapy, and QL for quantity limits. A drug that stays on the list but picks up a “PA” or “ST” code is a real change to how you refill.
3. The open enrollment packet. This is where the employer explains its own decisions in plain language — new program requirements, new vendors, plan options added or retired. Skim it for weight management, obesity, specialty, and step therapy. If the packet contradicts the SBC, the plan documents win, and that is worth raising with HR in writing.
What should I ask HR or the benefits line?
Copy these. Ask for answers in writing, and note the date you asked.
- “Is coverage for weight-management medications continuing under our 2027 plan? If it is being removed, on what date does it end?”
- “Are oral GLP-1 medications on the 2027 formulary, and at which tier?”
- “Is prior authorization changing for these medications in 2027 — new criteria, new documentation, or a new renewal interval?”
- “Is a step-therapy requirement being added, meaning I would have to try another medication first?”
- “Will enrollment in a weight-management or lifestyle program be required as a condition of coverage in 2027?”
- “If I have an approved prior authorization now, does it carry into 2027 or do I have to start over?”
That last question is the one people forget, and it is the one that most often causes a gap at the pharmacy in January.
What are my options if coverage is being dropped?
Look at your other plan choices first. If your employer offers more than one medical plan, the drug lists can differ between them. Open enrollment is the one window where switching costs you nothing but paperwork. Mercer’s September 2026 release also urges employees to compare their other medical plan options during open enrollment, noting that most employers offer more than one.12
Price the cash-pay channels. Manufacturers sell directly, and those prices do not depend on your employer.
- Novo Nordisk lists Wegovy self-pay pricing through NovoCare home delivery and its savings offer. As of October 25, 2026, the Wegovy pill is $149 per month for 1.5 mg, $199 for 4 mg, and $299 for 9 mg and 25 mg. Wegovy pens are $349 per month for 0.25 mg to 2.4 mg, and Wegovy HD 7.2 mg is $399. New patients pay $199 a month for their first 2 fills of the 0.25 mg or 0.5 mg pen, an offer that runs through December 31, 2026 (NovoCare, verified October 25, 2026).7
- Eli Lilly’s LillyDirect lists the same Zepbound self-pay prices for single-dose vials and the KwikPen: $299 per month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg to 15 mg when you refill within 45 days. If a refill comes more than 45 days after the last one, Lilly lists regular prices of $499 for 7.5 mg and $699 for 10 mg to 15 mg (LillyDirect, verified October 25, 2026).14 Lilly announced the vial prices in December 2025 and KwikPen self-pay pricing at LillyDirect and major pharmacies in March 2026.89
These prices move. Check the manufacturer page on the day you decide, and use our GLP-1 Price Index to compare what each channel is charging right now. If you want the arithmetic done for you across insurance, direct-purchase, and pharmacy options, run your situation through the Price Check tool.
Sort out your HSA and FSA elections during enrollment, not after. IRS Publication 502 says you can include in medical expenses the amounts you pay for prescribed medicines and drugs (IRS Publication 502, February 2026).10 If you expect to pay cash next year, your contribution election is what lowers the after-tax cost — and you generally cannot change it mid-year without a qualifying event. Confirm the rules with your plan administrator before you elect.
One caveat worth knowing. On January 1, 2027, Medicare’s negotiated price for Ozempic, Rybelsus, and Wegovy drops to $274 per 30-day supply, against a 2024 list price of $959 — a 71% discount (CMS, Negotiated Prices for Initial Price Applicability Year 2027).5 That price is for Medicare Part D. It does not set what your employer plan pays, and Mercer noted in November 2025 that the related manufacturer agreements “do not address prices charged to employer health plan sponsors and covered plan members.”13
A second January 1, 2027 change can reach some employer plan members. Novo Nordisk announced that the list price of Wegovy, Ozempic, and Rybelsus drops to $675 a month that day, and said the lower price is aimed at people whose out-of-pocket costs are linked to list price, such as those with high-deductible plans or coinsurance.15 If your plan charges a flat copay, the cut may not change what you pay. Our Wegovy 2027 price guide walks through who is likely to save.
What dates should I have on my calendar?
| Date | What happens |
|---|---|
| Aug 31, 2026 (passed) | Novo Nordisk’s “to be updated after August 31, 2026” date for Wegovy pill pricing has passed. As of Oct 25, 2026, NovoCare lists the pill at $149 (1.5 mg), $199 (4 mg), and $299 (9 mg and 25 mg) (NovoCare, verified Oct 25, 2026) |
| Fall 2026 (employer-set) | Your open enrollment window. Dates are set by your employer — check your benefits portal, not a national calendar |
| ≥30 days before plan year start | Deadline for a new SBC when coverage renews automatically (CMS, April 2026) |
| 60 days before effective date | Notice generally required for a mid-year change that would affect the SBC (CMS, April 2026) |
| Dec 31, 2026 | Last day of Novo Nordisk’s $199 new-patient Wegovy pen offer. Lilly’s Zepbound and Foundayo savings cards for commercially insured patients also say they expire on this date (NovoCare; Lilly, verified Oct 25, 2026)71617 |
| Jan 1, 2027 | Most employer plan years begin. Novo Nordisk’s announced $675 list price for Wegovy, Ozempic, and Rybelsus takes effect (Novo Nordisk, Feb 24, 2026). Medicare’s negotiated $274 price for Ozempic, Rybelsus, and Wegovy also takes effect, for Medicare Part D only (CMS, IPAY 2027) |
| Dec 31, 2027 | Medicare GLP-1 Bridge ends. CMS extended it from 2026 through December 31, 2027 after the BALANCE model did not launch in 2027. This applies to Medicare Part D beneficiaries, not employer plans (CMS, page updated July 13, 2026)6 |
The short version
Request your 2027 SBC and drug list. Read the prescription row and the exclusions list. Email HR the six questions above and keep the reply. Do it before your enrollment window closes, because after it closes your options narrow to cash-pay and an appeal.
This article covers cost, coverage, and administrative process only. It is not medical advice and does not recommend any medication. Talk to your prescriber about treatment decisions.
